Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.31 |
| ▸ | CNR2 | P34972 | 5/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485296 | 0.81 | ALDH1A1 (0.40) | ALDH1A1KMT2ANPC1POLBUSP2 | |
| SCHEMBL2220595 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL13850704 | 0.79 | TSHR (0.46) | KMT2ANPC1RAB9AATMPOLB | |
| SCHEMBL13942281 | 0.78 | CNR1 (0.35) | ALDH1A1KMT2ANPC1RAB9AATM | |
| SCHEMBL2863347 | 0.77 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL2223302 | 0.75 | ALDH1A1 (0.38) | ALDH1A1KMT2A | |
| SCHEMBL27468857 | 0.75 | ALDH1A1 (0.39) | ALDH1A1KMT2AUSP2TSHR | |
| SCHEMBL8621951 | 0.74 | ATM (0.36) | NPC1RAB9AATMPOLBCNR1 | |
| SCHEMBL11519053 | 0.73 | ALDH1A1 (0.35) | ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1582839 | 0.72 | MEN1 (0.36) | KMT2ANPC1RAB9AATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-11-08 | — | — | US | disclosed |
| EP-2516385-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012087372-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011087837-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | CBR3, CBR1, Q6ZSR9 | ALDH1A1 1771/4885KMT2A 1406/4885NPC1 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.